From the Research
The Cagrisema study demonstrated significant benefits of using a combination therapy of cagrilintide and semaglutide for weight management and glycemic control in patients with type 2 diabetes, with a mean weight loss of 15.6% and a mean HbA1c reduction of 2.2 percentage points at 32 weeks, as reported in the 2023 study published in the Lancet 1.
Key Findings
- The combination therapy of cagrilintide and semaglutide (CagriSema) resulted in superior weight loss and glycemic control compared to either medication alone.
- The mean change in HbA1c from baseline to week 32 was greater with CagriSema versus cagrilintide, but not versus semaglutide.
- The mean change in bodyweight from baseline to week 32 was greater with CagriSema versus both semaglutide and cagrilintide.
- Common side effects included nausea, vomiting, and diarrhea, which typically improved over time as the body adjusted to the medication.
Mechanism of Action
- Cagrilintide works as an amylin analog that reduces appetite and food intake.
- Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and increases satiety.
- Together, they target multiple pathways involved in weight regulation, creating a synergistic effect.
Clinical Implications
- This combination represents a promising advancement in obesity and type 2 diabetes treatment, offering patients a potentially more effective option than current single-agent therapies.
- Lifestyle modifications, including diet and exercise, remain essential components of any weight management program.
- The CagriSema combination therapy may be a valuable treatment option for patients with type 2 diabetes who require improved glycemic control and weight loss, as supported by the findings of the 2023 study 1.